NASDAQ:PTGX - Protagonist Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.98 +0.37 (+3.49 %) (As of 05/22/2019 05:11 AM ET)Previous Close$10.61Today's Range$10.39 - $11.2852-Week Range$5.49 - $14.36Volume125,900 shsAverage Volume165,454 shsMarket Capitalization$256.89 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California. Receive PTGX News and Ratings via Email Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX Previous Symbol CUSIPN/A CIK1377121 Webhttp://www.protagonist-inc.com/ Phone510-474-0170Debt Debt-to-Equity Ratio0.07 Current Ratio5.02 Quick Ratio5.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$30.92 million Price / Sales8.31 Cash FlowN/A Price / Cash FlowN/A Book Value$4.31 per share Price / Book2.55Profitability EPS (Most Recent Fiscal Year)($1.74) Net Income$-38,920,000.00 Net Margins-209.02% Return on Equity-40.78% Return on Assets-32.52%Miscellaneous Employees64 Outstanding Shares23,396,000Market Cap$256.89 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.58) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.01. The company earned $1.56 million during the quarter, compared to analyst estimates of $2.50 million. Protagonist Therapeutics had a negative return on equity of 40.78% and a negative net margin of 209.02%. View Protagonist Therapeutics' Earnings History. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Protagonist Therapeutics. What price target have analysts set for PTGX? 5 Wall Street analysts have issued 12 month price targets for Protagonist Therapeutics' stock. Their predictions range from $13.00 to $21.00. On average, they expect Protagonist Therapeutics' share price to reach $17.20 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics. What is the consensus analysts' recommendation for Protagonist Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics. Has Protagonist Therapeutics been receiving favorable news coverage? Media stories about PTGX stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Protagonist Therapeutics' key competitors? Some companies that are related to Protagonist Therapeutics include Eidos Therapeutics (EIDX), Radius Health (RDUS), Ra Pharmaceuticals (RARX), Homology Medicines (FIXX), Alder Biopharmaceuticals (ALDR), Rhythm Pharmaceuticals (RYTM), Athenex (ATNX), Omeros (OMER), MacroGenics (MGNX), Axovant Sciences (AXON), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), Clovis Oncology (CLVS), Myovant Sciences (MYOV) and Rocket Pharmaceuticals (RCKT). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Energy Transfer LP Unit (ET), Fate Therapeutics (FATE), ImmunoGen (IMGN), Ocular Therapeutix (OCUL), Strongbridge Biopharma (SBBP), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Novavax (NVAX), Omeros (OMER) and SCYNEXIS (SCYX). Who are Protagonist Therapeutics' key executives? Protagonist Therapeutics' management team includes the folowing people: Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)Dr. Richard S. Shames, Chief Medical Officer (Age 59)Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)Dr. Mark Smythe, VP of Technology (Age 54)Dr. Samuel R. Saks, Chief Devel. Officer (Age 64) When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.42%), Perceptive Advisors LLC (8.85%), Perceptive Advisors LLC (8.85%), BVF Inc. IL (4.80%), Dimensional Fund Advisors LP (2.84%) and Renaissance Technologies LLC (1.73%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics. Which institutional investors are selling Protagonist Therapeutics stock? PTGX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Spark Investment Management LLC, Wedge Capital Management L L P NC, Fosun International Ltd, FMR LLC, Acadian Asset Management LLC, Jacobs Levy Equity Management Inc. and Eqis Capital Management Inc.. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics. Which institutional investors are buying Protagonist Therapeutics stock? PTGX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Laurion Capital Management LP, Renaissance Technologies LLC, Tibra Equities Europe Ltd and Citigroup Inc.. View Insider Buying and Selling for Protagonist Therapeutics. How do I buy shares of Protagonist Therapeutics? Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $10.98. How big of a company is Protagonist Therapeutics? Protagonist Therapeutics has a market capitalization of $256.89 million and generates $30.92 million in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe. What is Protagonist Therapeutics' official website? The official website for Protagonist Therapeutics is http://www.protagonist-inc.com/. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected] MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 146 (Vote Outperform)Underperform Votes: 212 (Vote Underperform)Total Votes: 358MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What Does a Sell-Side Analyst Rating Mean? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.